ClinicalTrials.gg
CompletedNCT00323817Updated May 28, 2015

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

A Phase 2 interventional study of Z-338 in Functional Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 1 site in Belgium. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-05-28.

Sponsored by Zeria Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Planned enrollment
6th of 11
282 · median 282
Started
2006
with 2 others
Phase 2
5 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
7 of 11
Zeria Pharmaceutical

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 6th largest by planned enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 3rd registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects presenting diagnosis of FD as defined by the Rome II
  • Subjects presenting postprandial fullness and/or Early satiety should be the most bothersome symptom

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
282 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Global subject Outcome Assessment

    Time frame: 12 month

Secondary outcomes

  1. Individual symptom

    Time frame: 12 month

07

Study locations

1 site
  • Leuven University
    Leuven, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Apr 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2006
First posted
May 10, 2006
Start
Apr 2006
Primary completionActual
Apr 2009
CompletionActual
Oct 2009
Last update
May 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00323817
First posted
May 10, 2006
Start date
Apr 2006
Primary completion
Apr 2009
Completion
Oct 2009
Last update
May 28, 2015

Study contacts

Jan Tack, PhD, MD
principal investigator · Universitaire Ziekenhuizen KU Leuven
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion